ACE2 News and Research

RSS

Immunogenicity and safety of COVID-19 subunit vaccine Nanocovax in animal models

Researchers have developed Nanocovax, a COVID-19 subunit vaccine based on recombinant protein technology to produce the extracellular (soluble) portion of the S protein of SARS-CoV-2.

9 Dec 2021

SARS-CoV-2 variants are evolving new ways to evade antibodies and vaccines

Continued replication of severe acute respiratory syndrome-associated coronavirus 2 (SARS-CoV-2) under selective pressure from natural and vaccine-induced immunity has led to the emergence of variants of concern (VOCs) with increased transmissibility or virulence.

8 Dec 2021

Omicron binds to ACE2 with high affinity, enhancing its transmissibility and infectivity

...

8 Dec 2021

Equilibrium simulation of SARS-CoV-2 spike protein highlights its global conformational characteristics

A team of researchers set out to build a full-length, membrane-embedded spike to study its conformational dynamics at the atomic level using molecular dynamics simulations to understand better how this important component of the virus machinery works.

8 Dec 2021

Quantum mechanical characterization of SARS-CoV-2 Omicron variant interaction with human ACE2 receptor

Researchers from Universite Grenoble Alpes have been investigating the changes in the Omicron variant RBD and how they affect ACE2 binding.

8 Dec 2021

Computational comparison of SARS-CoV-2 Delta and Omicron variant binding affinity with ACE2

Researchers from the Management and Science University in Malaysia have used computational tools to investigate the new variant.

8 Dec 2021

Does a COVID-19 vaccine booster improve the immune response of a poor responder?

A new study has focussed on determining the levels of nAb in individuals who received the second and third doses of the RNA vaccines developed by Pfizer and Moderna.

8 Dec 2021

SARS-CoV-2 Delta variant changes receptor binding domain conformation to escape host antibodies

Researchers investigate the conformational dynamics of the SARS-CoV-2 RBD using the atomistic molecular dynamics simulation method.

7 Dec 2021

Homologous mRNA and heterologous vaccines elicit high immune responses

New study findings show that homologous mRNA or heterologous vaccination induces the highest immune responses due to high RBD- and S1-specific antibodies.

7 Dec 2021

Possible impact of spike protein mutations on SARS-CoV-2 Omicron variant

The current study not only analyses the mutations in the Omicron spike variant but classifies various combinations of spike mutations into groups.

7 Dec 2021

Impact of post-translational modifications in the pathogenicity of SARS-CoV-2

A new study provides understanding of the intricate roles and functions of the different elements of spike proteins and shows how the spike protein samples a crowded surface of its host cell via the glycans.

7 Dec 2021

Study suggests algal polysaccharide may be a promising anti-COVID-19 candidate

Researchers from the Rensselaer Polytechnic Institute have been investigating the potential of rhamnan sulfate as an antiviral agent.

7 Dec 2021

Scientists develop and characterize variant-specific vaccines against SARS-CoV-2

In a recent study conducted at Yale University, USA, scientists have investigated the immunogenicity of mRNA-based coronavirus disease 2019 (COVID-19) vaccine candidates encoding the spike proteins of different severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants. The findings reveal that the vaccines induce robust immune responses against SARS-CoV-2 variants. The study is currently available on the bioRxiv* preprint server.

6 Dec 2021

ACE2 News and Research

Immunogenicity and safety of COVID-19 subunit vaccine Nanocovax in animal models

SARS-CoV-2 variants are evolving new ways to evade antibodies and vaccines

Omicron binds to ACE2 with high affinity, enhancing its transmissibility and infectivity

Equilibrium simulation of SARS-CoV-2 spike protein highlights its global conformational characteristics

Quantum mechanical characterization of SARS-CoV-2 Omicron variant interaction with human ACE2 receptor

Computational comparison of SARS-CoV-2 Delta and Omicron variant binding affinity with ACE2

Does a COVID-19 vaccine booster improve the immune response of a poor responder?

SARS-CoV-2 Delta variant changes receptor binding domain conformation to escape host antibodies

Homologous mRNA and heterologous vaccines elicit high immune responses

Possible impact of spike protein mutations on SARS-CoV-2 Omicron variant

Impact of post-translational modifications in the pathogenicity of SARS-CoV-2

Study suggests algal polysaccharide may be a promising anti-COVID-19 candidate

Scientists develop and characterize variant-specific vaccines against SARS-CoV-2

SARS-CoV-2 S2 immunization as a pan-coronavirus vaccine approach

Scientists find infection of sustentacular cells in the olfactory epithelium of COVID-19 patients

SARS-CoV-2 ORF10 degrades mitochondrial antiviral signaling protein to suppress immune response

New test can quickly and easily assess antibody effectiveness against COVID-19 variants

Telomeric DNA damage response may increase susceptibility of elderly people to COVID-19

Quantum mechanical model offers insights into SARS-CoV-2 evolution

Novel peptide-antibody fusion molecule enhances SARS-CoV-2 variant neutralization

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News